Decheng Capital

In The News

November 15, 2022	CG Oncology Raises $120 Million in Oversubscribed Series E Financing to Advance Clinical-Stage Urologic Oncology Pipeline
September 28, 2022	Professor Dennis Lo, Decheng's Advisor, Wins 2022 Lasker Award
September 22, 2022	Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing
September 20, 2022	Alpine Immune Sciences Announces Pricing of $100 Million Public Offering
September 13, 2022	ACELYRIN, INC. Announces $300 Million Series C Financing to Accelerate Phase 3 Development of Izokibep, a Unique IL-17A Inhibitor to Treat Inflammatory Diseases
June 2, 2022	Watchmaker Genomics Raises $40M Series A Financing to Accelerate Growth and Expand Clinical Sequencing Product Offerings
June 2, 2022	Upstream Bio Launches with $200M Series A Financing to Advance Novel Therapeutics for Allergic and Inflammatory Diseases
May 31, 2022	Regeneron Completes Acquisition of Checkmate Pharmaceuticals
May 17, 2022	Mirvie Raises $60 Million For Blood Test To Predict Pregnancy Complications
April 19, 2022	Regeneron to Acquire Checkmate Pharmaceuticals and its Investigational Immune Activator for Potential Use in Multiple Tumor Types
March 18, 2022	Apexigen and Brookline Capital Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Immuno-oncology Company
January 20, 2022	ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma
January 10, 2022	Bayer and Mammoth Biosciences to Collaborate on Novel Gene Editing Technology
January 5, 2022	Study Published in Nature Shows Mirvie Can Predict Pregnancy Complications Months Before They Happen Using New, Proprietary RNA Platform